Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is facing challenges with its ongoing transition from its DOS platform to Ignite, leading to potential customer attrition and down-selling. Despite this, there are positive signs with the company signing 32 new platform customers in 2025, exceeding its revised target and indicating traction with the new platform. The revenue impact in FY26 and FY27 related to this transition is being better defined, with an expected retention of at least $22M of the $52M ARR pool and an estimated $30M churn or down-sell, resulting in a back half stepdown in revenue.

Bears say

Health Catalyst is facing headwinds in the form of booking delays for its data platform and analytics applications due to migration-related challenges and reduced retention of ARR related to DOS decisions. This has led to a forecast for a decline in revenue and adjusted EBITDA for fiscal year 2026, as well as a lowered price target. While there is potential for value in the company's assets and potential deals in the market, the negative outlook is based on the current challenges and uncertain future performance.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.